Sort
3,198 grants matching “mrna vaccine”
Control of protective immunity by innate pathways sensing bacterial viability
$423,750Julie Magarian Blander · Icahn School Of Medicine At Mount Sinai · R01 · FY2014 · AI
Control of protective immunity by innate pathways sensing bacterial viability
$423,750Julie Magarian Blander · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · AI
Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires
$423,633Heng Li · Dana-Farber Cancer Inst · U01 · FY2020 · CA
Listeria Hemolysin and Escape from a Vacuole
$423,451Daniel A Portnoy · University Of California Berkeley · R01 · FY2009 · AI
Role of Tick Metalloprotease Inhibitors in the Transmission of Borrelia burgdorferi
$423,106Albert Mulenga · Texas A&M Agrilife Research · R21 · FY2025 · AI
CC Chemokine Secretion to Protect Antigen-Specific CD4 T Cells from HIV
$422,604Catarina E Hioe · New York University School Of Medicine · R01 · FY2009 · AI
CC Chemokine Secretion to Protect Antigen-Specific CD4 T Cells from HIV
$422,500Catarina E Hioe · New York University School Of Medicine · R01 · FY2010 · AI
Vaccination responses in lung transplant recipients
$422,438Mark Robert Nicolls · Stanford University · U01 · FY2023 · HL
Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis
$422,266Kent E. Kester · International Aids Vaccine Initiative · R61 · FY2023 · AI
Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses.
$421,000Magnus Adrian Gero Hoffmann · California Institute Of Technology · DP5 · FY2022 · OD
Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses.
$421,000Magnus Adrian Gero Hoffmann · California Institute Of Technology · DP5 · FY2023 · OD
Role of HSV Induced RNA Degradation in Pathogenesis
$420,750David A. Leib · Dartmouth College · R01 · FY2010 · EY
Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires
$420,221Xiaole Shirley Liu · Dana-Farber Cancer Inst · U01 · FY2019 · CA
Defining the molecular interactions within nanoparticles that enable delivery of long nucleic acids
$419,679Daniel John Siegwart · Ut Southwestern Medical Center · R01 · FY2023 · EB
Defining the molecular interactions within nanoparticles that enable delivery of long nucleic acids
$419,679Daniel John Siegwart · Ut Southwestern Medical Center · R01 · FY2022 · EB
Accelerating the translation of oligonucleotide therapeutics by enhancing delivery
$419,398Aimee L Edinger · University Of California-Irvine · R21 · FY2025 · TR
Can SARS-CoV-2 proteins accelerate Abeta pathology in fly and mouse models of AD?
$419,375Diego E Rincon-Limas · University Of Florida · R21 · FY2025 · AG
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
$419,267Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · R01 · FY2017 · AI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
$419,267Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · AI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
$419,267Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
$419,267Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · AI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
$419,267Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · AI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle
$419,125Michael G Roth · Ut Southwestern Medical Center · R01 · FY2010 · AI
Harnessing the Malarial Immunity Omics Landscape in Vaccinated and Unvaccinated Children for Improved Therapeutic Strategies
$418,896Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2025 · AI
Mechanisms of platelet reprogramming during influenza infection
$418,750Milka Koupenova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · HL